BACKGROUND AND PURPOSE: (13)C-urea may be a suitable marker to assess the in vivo fate of colon-targeted dosage forms given by mouth. We postulated that release in the colon (urease-rich segment) of (13)C-urea from colon-targeted capsules would lead to fermentation of (13)C-urea by bacterial ureases into (13)CO(2). Subsequent absorption into the blood and circulation would lead to detectable (13)C (as (13)CO(2)) in breath. If, however, release of (13)C-urea occurred in the small intestine (urease-poor segment), we expected detectable (13)C (as (13)C-urea) in blood but no breath (13)C (as (13)CO(2)). The differential kinetics of (13)C-urea could thus potentially describe both release kinetics and indicate the gastrointestinal segment of release. EXPERIMENTAL APPROACH: The in vivo study consisted of three experiments, during which the same group of four volunteers participated. KEY RESULTS: The kinetic model was internally valid. The appearance of (13)C-in breath CO(2) (F(fermented)) and the appearance of (13)C in blood as (13)C-urea (F(not fermented)) show a high inverse correlation (Pearson's r=-0.981, P= 0.06). The total recovery of (13)C (F(fermented)+F(not fermented)) averaged 99%, indicating complete recovery of the administered (13)C via breath and blood. (13)CO(2) exhalation was observed in all subjects. This indicates that (13)C-urea was available in urease-rich segments, such as the caecum or colon. CONCLUSIONS AND IMPLICATIONS: In this proof-of-concept study, (13)C-urea was able to provide information on both the release kinetics of a colon-targeted oral dosage form and the gastrointestinal segment where it was released.
BACKGROUND AND PURPOSE: (13)C-urea may be a suitable marker to assess the in vivo fate of colon-targeted dosage forms given by mouth. We postulated that release in the colon (urease-rich segment) of (13)C-urea from colon-targeted capsules would lead to fermentation of (13)C-urea by bacterial ureases into (13)CO(2). Subsequent absorption into the blood and circulation would lead to detectable (13)C (as (13)CO(2)) in breath. If, however, release of (13)C-urea occurred in the small intestine (urease-poor segment), we expected detectable (13)C (as (13)C-urea) in blood but no breath (13)C (as (13)CO(2)). The differential kinetics of (13)C-urea could thus potentially describe both release kinetics and indicate the gastrointestinal segment of release. EXPERIMENTAL APPROACH: The in vivo study consisted of three experiments, during which the same group of four volunteers participated. KEY RESULTS: The kinetic model was internally valid. The appearance of (13)C-in breath CO(2) (F(fermented)) and the appearance of (13)C in blood as (13)C-urea (F(not fermented)) show a high inverse correlation (Pearson's r=-0.981, P= 0.06). The total recovery of (13)C (F(fermented)+F(not fermented)) averaged 99%, indicating complete recovery of the administered (13)C via breath and blood. (13)CO(2) exhalation was observed in all subjects. This indicates that (13)C-urea was available in urease-rich segments, such as the caecum or colon. CONCLUSIONS AND IMPLICATIONS: In this proof-of-concept study, (13)C-urea was able to provide information on both the release kinetics of a colon-targeted oral dosage form and the gastrointestinal segment where it was released.
Authors: Jürgen K Willmann; Nicholas van Bruggen; Ludger M Dinkelborg; Sanjiv S Gambhir Journal: Nat Rev Drug Discov Date: 2008-07 Impact factor: 84.694
Authors: Valentine C Ibekwe; Fang Liu; Hala M Fadda; Mandeep K Khela; David F Evans; Gary E Parsons; Abdul W Basit Journal: J Pharm Sci Date: 2006-12 Impact factor: 3.534
Authors: K Verbeke; V de Preter; K Geboes; T Daems; G van den Mooter; P Evenepoel; P Rutgeerts Journal: Aliment Pharmacol Ther Date: 2005-01-15 Impact factor: 8.171
Authors: R C A Schellekens; F Stellaard; D Mitrovic; F E Stuurman; J G W Kosterink; H W Frijlink Journal: J Control Release Date: 2008-08-23 Impact factor: 9.776
Authors: Marina J M Maurer; Reinout C A Schellekens; Klaus D Wutzke; Gerard Dijkstra; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink; Frans Stellaard Journal: Pharm Res Date: 2012-03-16 Impact factor: 4.200
Authors: Reinout C A Schellekens; Frans Stellaard; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink Journal: Br J Clin Pharmacol Date: 2011-12 Impact factor: 4.335
Authors: Mamoudou Maiga; Keira Cohen; Bocar Baya; Geetha Srikrishna; Sophia Siddiqui; Moumine Sanogo; Anou M Somboro; Bassirou Diarra; Mariam H Diallo; Varun Mazumdar; Christian Yoder; Susan Orsega; Michael Belson; Hamadoun Kassambara; Drissa Goita; Robert L Murphy; Sounkalo Dao; Michael Polis; Souleymane Diallo; Graham S Timmins; Lori Dodd; Ashlee M Earl; William R Bishai Journal: J Breath Res Date: 2016-08-17 Impact factor: 3.262
Authors: Jacoba M Maurer; Reinout C A Schellekens; Hèlen M van Rieke; Christoph Wanke; Ventzeslav Iordanov; Frans Stellaard; Klaus D Wutzke; Gerard Dijkstra; Margot van der Zee; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240